Perspectives in Veterinary Pharmacology and Toxicology by Arturo Anadón
September 2016 | Volume 3 | Article 821
Specialty Grand challenGe
published: 13 September 2016
doi: 10.3389/fvets.2016.00082
Frontiers in Veterinary Science | www.frontiersin.org
Edited by: 
Mary M. Christopher, 
University of California Davis, USA
Reviewed by: 
Francesca Caloni, 
University of Milan, Italy
*Correspondence:
Arturo Anadón  
aanadon@ucm.es
Specialty section: 
This article was submitted to 
Veterinary Pharmacology 
and Toxicology, 
a section of the journal 
Frontiers in Veterinary Science
Received: 16 August 2016
Accepted: 01 September 2016
Published: 13 September 2016
Citation: 
Anadón A (2016) Perspectives in 
Veterinary Pharmacology and 
Toxicology. 
Front. Vet. Sci. 3:82. 
doi: 10.3389/fvets.2016.00082
perspectives in Veterinary 
pharmacology and toxicology
Arturo Anadón*
Department of Toxicology and Pharmacology, Faculty of Veterinary Medicine, Universidad Complutense de Madrid, Madrid, 
Spain
Keywords: veterinary pharmacology and toxicology, antimicrobial resistance, contaminants and residues, 
environment, regulatory aspects, new challenges
Veterinary pharmacology and toxicology are being increasingly recognized as important disciplines 
and were also rapidly changing and evolving in the mid-twentieth century. By the mid-1950s, phar-
macology and toxicology were a highly active area of veterinary medicine; veterinary pharmacology 
and toxicology emerged as new disciplines, closely related, because they were involved in developing 
new compound, particularly new antimicrobials and antiparasitics to control infection diseases, and 
analgesic/non-steroidal anti-inflammatory drugs affecting different animal species. The research 
and development cost of new antimicrobials that must fulfill the new regulatory requirements is 
considered high; in drug development projects, toxicology closely linked with pharmacology and 
pharmacokinetics is decisive in the success or failure of a new drug candidate. During the last 
years, the following new antimicrobial active substances have been authorized for use in veterinary 
medicine: difloxacin (belonging to the class fluoroquinolones, authorized in 1998 after marketing 
of enrofloxacin in 1987), valnemulin (a pleuromutilin, 1999), pirlimycin (a lincosamide, 2001), 
tulathromycin (a macrolide, 2003), tylvalosin (a macrolide, 2004), ceftiofur (a third-generation 
cephalosporin, 2005), cefovecin (a third-generation cephalosporin, 2006), gamithromycin (a mac-
rolide, 2008), pradofloxacin (a fluoroquinolone, 2011), and tildipirosin (a macrolide, 2011). None 
of these antimicrobials belongs to a new class of antimicrobials. It is known that most veterinary 
drugs derive from either the human pharmaceutical industry (antibiotics, analgesic, antiobesity, 
anticancer, cardiovascular) or the plant protection products (insecticides, parasiticides). Like 
veterinary medicine, veterinary pharmacology and toxicology is not an easy matter because of 
multiplicity of animal species as well as breed, age, sex, and (patho)physiological status concerned 
that may respond differently to certain drugs, food, feed, pesticides, and industrial products as well 
as contaminants or toxins. The inter- and intraspecies differences as well the variability within and 
across animal populations are the essence of veterinary pharmacology and toxicology. It is know the 
species differences in the metabolism and excretory processes of different chemical compounds. In 
the 60s of the twentieth century, the extrapolation dose regimens from one species to another was 
a common practice; however, nowadays it is known that pharmacokinetics/toxicokinetics (PK/PD) 
differences remain for drugs, pesticides, contaminants, or toxins that is the cornerstone of vet-
erinary pharmacology and toxicology. Moreover, the analytical techniques to measure plasma/
tissue concentrations of xenobiotics are changed and the sensibility been improved. Analytical 
methods whether intended for use in pharmacokinetic (PK) and metabolism studies, residue 
depletion studies, or regulatory control programs for residues of veterinary drugs and pesticides, 
and contaminants, share a common subset of validation criteria. Performance characteristics to be 
determined for all method validation include specificity, accuracy, precision, limit of detection, limit 
of quantitation, susceptibility to interference, and information on method calibration. Practicability, 
applicability under normal laboratory conditions, and ruggedness are the additional criteria for the 
evaluation of regulatory methods. Residue programs consist of two principal activities: monitoring 
and surveillance. For monitoring drugs having maximum residue limits (MRLs), animal tissues, 
such as liver, kidney, muscle, milk, eggs, honey, or fat, are selected. Another group of samples/
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matrices frequently used are animal feed and drinking water as 
well as manure, urine, and hair. They are mostly used to monitor 
prohibited substances and can be taken prior to slaughtering. 
Analyzing hair has gained some popularity because it has been 
demonstrated that anabolic steroids can be detected in hair a long 
time after application of the drugs – that is, when residues cannot 
be detected any more in urine or manure. It has been suggested 
that the hair analysis is a strong means to control the illegal use 
of clenbuterol in animal production, and samples are available 
from living as well as slaughtered cattle. The thyroid gland is used 
to monitor the use of thyreostatics; the eye, vitreous humor, or 
retina (1, 2) have been suggested as tissues for residue screening, 
such as clenbuterol, ractopamine hydrochloride, and zilpaterol 
hydrochloride with β-adrenoceptor activity. Hair/feathers (both 
pigmented and non-pigmented) also show this accumulation 
effect; the concentration of clenbuterol in bovine brown or white 
hair was found to be about one-third that in black hair (3).
By the mid-1950s, veterinary toxicology was a highly active 
area of veterinary medicine. Toxicology was once the science 
of poisons and intoxication, but currently toxicology should be 
regarded as the “science of safety” because it is essential in ensur-
ing safety of food, feed, drugs, pesticides, and industrial products 
used in daily life (4). Biochemical and molecular interactions 
were discussed, and the tools of other disciplines were brought 
to focus upon the problems of domestic animal poisonings. An 
understanding of mechanisms, potential benefits, and risks of 
antidotes is essential for clinicians who manage poisoned ani-
mals. Of the dozens of antidotes currently available, only a few are 
regularly used. These include activated charcoal, acetylcysteine, 
naloxone, sodium bicarbonate, atropine, flumazenil, therapeutic 
antibodies, and various vitamins. Even then, most are used in a 
minority of poisonings. There is little randomized trial evidence 
to support the use of most antidotes. Consequently, decisions 
about when to use them are often based on a mechanistic 
understanding of the poisoning and the expected influence of 
the antidote on the patient’s clinical course. Importantly, most 
poisoned animal patients who reach veterinary clinic/hospital 
can recover with supportive care alone. In more serious poison-
ings, decisions regarding antidote use are generally guided by 
a risk/benefit assessment based on low quality evidence. With 
it, a new generation of veterinarian emerged. The developing 
veterinary toxicologist had to understand physiology, pathology, 
and chemistry, but with extensive knowledge of qualitative and 
quantitative analytical techniques. Judgment of clinical episodes 
and knowledge of metabolic and excretory processes were 
needed. Toxicology becomes intimately familiar with pharma-
cology and the molecular action of a wide variety of chemicals. 
Toxicology and pharmacology can be considered as the same 
discipline on two different ends of spectrum; pharmacology is 
the study of drugs used at doses to achieve therapeutic effects on 
an organism, while toxicology is the study of toxicants that pro-
duce harmful effect on an organism. Understanding treatments 
to be administered for specific intoxications was necessary. In 
conclusion, there are often confusing and confounding assort-
ment of signs, lesions, and analytical results to reach rational 
interpretations and conclusions for the numerous problems 
being solved (5).
The veterinary medicine profession was initially focused on 
domestic animals, particularly those used for food consumption, 
and horse for transportation. With the growth of more special-
ized agriculture and production practices, the veterinary profes-
sion with its linkage to domestic livestock, stimulated growth of 
veterinary pharmacology and toxicology. Later on, the veterinary 
profession was concerned to a growing population of companion 
animals, including horses (used in equine activities relating to 
competitive sports and leisure activities), dogs and cats (as inte-
gral family members), and other animal species (i.e., will/exotic 
animals) (6). The antiparasitic, analgesics, antiobesity, cardiovas-
cular, and anticancer drug market for dogs and cats has grown 
abundantly, which has been the result of the progress of the vet-
erinary pharmacology and toxicology. In both fields of veterinary 
medicine (i.e., domestic and companion animals, and wild/exotic 
animals) was strengthened as observation-based medical practice 
was complemented and, ultimately, supplemented by science-
based medicine. During this period, veterinary pharmacologists 
and toxicologists began to play an important role in veterinary 
medical diagnostic laboratories (6). With the strengthening of 
the science base of veterinary medicine, including the quality of 
the science in the veterinary medical curriculum, the emergence 
of the comparative medicine character of veterinary medicine 
became more apparent and was enhanced (7). Comparative 
Medicine is a distinct discipline of experimental medicine that 
uses animal models of human and animal disease in translational 
and biomedical research. Biomedical research included compara-
tive pharmacology, toxicology, and pathology. These changes in 
the profession were accompanied by increased involvement of 
veterinarians in research on the species of traditional concern 
to the profession, domestic, and companion animals (8), and to 
participation in a broader range of biomedical research activities, 
involving use of the traditional laboratory animal species, driven 
largely by concern for human health (7). More and more veteri-
narians are now conducting pharmacological and toxicological 
research as their primary mission.
Pharmacology and toxicology are translational sciences. 
Pharmacology translates fundamental insights into drug action 
and fate into clinical therapy. Toxicology translates science, 
transferring knowledge from fundamental science into practi-
cal applications to safeguard animal health, human health, and 
the environment. Toxicology as translational science uses basic 
and clinical science to solve problems in toxicologically relevant 
fields. A high level of basic scientific research in toxicology is the 
prerequisite to assessing emerging risks in the process of devel-
oping drugs, chemicals, and materials (9). Nowadays, veterinary 
pharmacology and toxicology should be regarded as disciplines 
contributing to the paradigm “One World, One Health,” reducing 
risk at the animal–human–ecosystems interface.
The development of veterinary pharmacology and toxicology 
is the same as that for humans, although between human and 
veterinary medicine, there are differences in size and economic 
factors (10). The evolution of veterinary pharmacology and toxi-
cology occurred concurrently with evolution of its two roots; the 
profession of veterinary medicine and the science of pharmacol-
ogy and toxicology. The veterinary pharmacologist and toxicolo-
gists recognize the necessity of considering the various animal 
3Anadón Perspectives in Veterinary Pharmacology and Toxicology
Frontiers in Veterinary Science | www.frontiersin.org September 2016 | Volume 3 | Article 82
species of concern as a main activity (6). Traditional indicators 
of target organ toxicity used in drug preclinical safety studies 
consist of a battery of clinical pathology parameters in blood 
and urine coupled with histopathologic examination of altered 
tissues, often measured in multidose toxicity studies. In recent 
years, the expansion of knowledge at the molecular and cellular 
level has provided the opportunity for considering the addition 
of a multitudinous of new endpoints to pharmacological and 
toxicological evaluations (11). Industry and regulatory agencies 
expect that new and better efficacy and toxicity biomarkers (the 
latter also known as safety biomarkers) will play an important 
role in improving key aspects of the drug development process. 
Successful translation of many biomarkers into clinical practice 
is now increasing. It is well known to the veterinary clinician, 
pharmacologist, and toxicologist and to physicians that biomark-
ers have been used in both human and veterinary medicine for 
centuries. In some cases, measurement of the biomarkers present 
in body fluids, urine, or exhaled breath serve as an indicator of 
exposure or, even, dose of a drug or toxicant. The application of 
genomics has already proved useful in fundamental research and 
for gaining a mechanistic understanding of drug activity (12).
New biomarkers of exposure will continue to be proposed. 
For each potential biomarker of exposure, it will be necessary 
to conduct experiments to validate the utility of the biomarker. 
A  special challenge relates to recognizing the dynamics of the 
pharmacokinetics/toxicokinetics of various drugs and toxicants 
and establishment of quantitative relationships between exposure 
and dose at any particular time over the course of the intoxication.
The potential list of biomarkers for efficacy and toxic responses 
is seemingly endless. In all fields of medicine, from different kinds 
of cancer to various functional diseases of every organ system, 
new molecular markers are being identified on a regular basis. 
The challenge for pharmacologists and toxicologists is to con-
sider, from among this array of opportunities, which biomarkers 
are sufficiently well validated with regard to their linkage to 
diseases and sufficiently reasonable in cost to warrant their use 
in exposure–response studies. This includes consideration of the 
new and highly sophisticated genomic tools. There is a special 
challenge in designing validation studies to make certain that 
the experimental design is directed toward identifying specific 
disease-related endpoints or toxicant-related effects rather than 
merely being another, albeit more sophisticated, marker of non-
specific toxic effects. A serious issue in many previous validation 
studies has been the use of a single high exposure level and a few 
short-term observation times. Such studies are unable to evaluate 
exposure-related changes in biomarkers and may not be able to 
identify toxicant-specific changes. Most safety biomarkers have 
been used in safety assessment for many years without being for-
mally qualified, and many of them show deficiencies with respect 
to sensitivity, specificity, and predictive value (11, 13). With that 
in mind, during the development of biomarkers, the following 
steps should be followed: (1) identification, (2) preclinical quali-
fication, and (3) clinical qualification and diagnostic use (14).
Veterinary pharmacology and toxicology is in some countries 
a unique discipline, but in others is completely split as veterinary 
pharmacology and veterinary toxicology because of their devel-
opment and complexity; the veterinary toxicology studies are not 
only focused in drugs but also addressed other subjects such as 
food and feed safety, plant protection products, and industrial 
chemicals among others.
Veterinary pharMacOlOGy
Veterinary pharmacology is defined as the study of the properties 
of drugs and all aspects of their interaction with living organisms. 
Drugs include any chemical agent (other than food) used in the 
treatment, cure, prevention or diagnosis of disease, or the control 
of physiological processes (10). The science of pharmacology 
draws on the knowledge and methods of many allied clinical 
and non-clinical disciplines, including chemistry, biochemistry, 
biology, physiology, pathology, toxicology, and medicine.
Veterinary pharmacology is an experimental science dealing 
with the properties of drugs and their effects on living systems. It 
has included study of sources of drugs (pharmacognosy), magni-
tude, and time course of the observed pharmacological effect on 
the body pharmacodynamics (PD), relationship between admin-
istered doses, the observed biological fluid/tissue concentrations 
of the drug, and time in the body pharmacokinetics (PK), use 
in the treatment of diseases (therapeutics), and poisoning effects 
(toxicology).
The residue definition for veterinary drugs in edible 
commodities of animal origin is obtained from metabolism 
studies conducted in target species and livestock animals. The 
metabolites, degradation products, and other transformation 
products are typically identified and quantified with methods 
based on the use of substances labeled with radioactive isotopes. 
Metabolites obtained in these studies are qualitatively compared 
with metabolites identified in laboratory animals, usually rats, to 
ensure that substances occurring in significant amounts in edible 
commodities have been included in the toxicological testing or to 
determine whether additional testing of individual metabolites is 
necessary. Metabolism studies in laboratory animals also serve to 
identify mammalian metabolism.
Drug–drug and drug–feed additive interactions deserve espe-
cial attention: a particular reference should be made to side effects 
and residue formation, and the likelihood of these interactions 
has to become part of the evaluation procedure. However, the 
most effective approach to prevent the occurrence of residues is 
certainly the rationally based selective use of veterinary drugs for 
which well-educated veterinarians are needed.
The form and the distribution of the residues that result from 
each authorized mode of application in each species should be 
determined, and the depletion of the residues from edible tissues 
or animal-derived foods should be studied. Total residue and 
metabolism study provides information to establish the appropri-
ate marker residue (is the parent drug or any of its metabolites or 
a combination of any of these with a known relationship to the 
concentration of the total residue in each of the various edible 
tissues at the expected withdrawal time) and to determine the 
target tissue. A “marker residue” should be identified, which is 
usually the form of the drug (parent compound or metabolite) 
that is found at the highest concentration for the longest period 
in the target food. The tissue in which the highest residues are 
found is usually designated as a “target tissue” (represents the 
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edible carcass from which residue depletes most slowly and is the 
edible tissue selected to monitor for the marker residue in the 
target animal) (15).
The extent to which such differences can be extrapolated to 
humans should be evaluated; for example, many sex differences 
in metabolism observed in rats do not occur in humans. The 
enzymes involved in the metabolism of foreign compounds rep-
resent the most important source of interspecies differences and 
human variability in the biodisposition of the compound and, for 
many cases, in the generation of toxic effects.
A further important role of such in  vitro experiments is to 
investigate similarities and differences between humans and test 
species in the metabolism and effects of xenobiotics that may 
provide information critical to the extrapolations normally used 
in risk assessment.
Veterinary clinical pharmacology is a subset matter of the 
broad study of pharmacology and is devoted to the study of the 
clinical effects of drugs on animal patients with a goal of optimiz-
ing therapeutic dosage regimens. Knowledge of the PK and PD 
properties of drugs and their toxic effects is inherent in this veteri-
nary discipline. Clinical pharmacology in the veterinary setting 
is the clinical discipline devoted to the optimal use of drugs in 
veterinary patients, maximizing their prophylactic or therapeutic 
benefits while ensuring that the adverse consequences of drug use 
are minimized.
Veterinary clinical pharmacology is a clinical science that 
integrates disease pathophysiology with fundamental concepts 
of pharmacology to provide a rational basis for drug therapy in 
animal patients (10). Brown (16) states that the goal of veterinary 
clinical pharmacology is to apply the principles of pharmacol-
ogy to more successfully treat animal patients and to more 
rationally use medications in veterinary medical practice. A 
fundamental understanding of veterinary clinical pharmacology 
is essential for good clinicians. The demonstration of efficacy 
includes the following test phases: (1) description of the mode 
of action, (2) determination of dose and dosing interval(s), (3) 
dose confirmation trials, including persistent efficacy trials, and 
(4) where applicable, clinical field trials. Similarly, knowledge of 
the pharmacological action of drugs is meaningless unless one 
also has a basic understanding of the relevant physiology and 
pathophysiology of the system or tissue adversely affecting the 
health or welfare of the patient.
There are methods for conducting clinical efficacy studies for 
infectious diseases and non-infectious diseases. These approaches 
may include studies in a model of the disease, or alternate meth-
ods for evaluating the response to the therapeutic agent in order 
to get utility in the new animal drug development process (16). 
The choice of the clinical endpoint is critical and determines the 
study design. There are many compounds (e.g., antibacterials, 
anthelmintics), where efficacy endpoints are reasonably easy to 
identify (i.e., clinical and bacteriological response as determined 
by the use of appropriate clinical, postmortem, and bacteriologi-
cal diagnostic methods, and the determination of mortality rate; 
decrease in worm count, decreased temperature). However, 
identification of efficacy endpoints for non-antibacterial or non-
growth enhancement compounds is more difficult to determine. 
Veterinary pharmacology aids in the identification of appropriate 
endpoints, helping to make them more quantitative, reproduc-
ible, and representative of the clinical field situation. Whereas 
“therapeutics” is a term describing treatment of disease in 
general and includes use of drugs, surgery, radiation, behavioral 
modification, and other modalities. Demonstration of efficacy of 
veterinary drugs is usually dealing with general requirements for 
the assessment of efficacy of such products. Depending on the 
aim of the trial, it can be classed in one of the following three 
categories: (1) confirmatory, (2) exploratory, or (3) composite 
trial. Confirmatory trials can concern dose-determination trials, 
dose confirmation trials as well as controlled field trials.
For antimicrobials, the dose, the dosing interval, and the 
number of administrations of product should always be justified 
by considering the PK/PD relationship, if established, as well 
as the severity of the disease. In some cases, where the PK/PD 
relationship is well established using validated models, it may be 
possible to omit dose-determination studies and to evaluate in a 
clinical trial the efficacy of one or a very few regimens. However, 
to be acceptable, the choice of the PK/PD parameter considered 
as best predictive of efficacy must be prospectively justified by 
independent data.
A prerequisite for clinical studies is to perform toxicological 
testing of new drugs with the objective to know potential undesir-
able effects of the drug candidates and drugs in the therapeutic 
range and above (17).
pharMacOKineticS/tOXicOKineticS
Pharmacokinetics (PK) is the study of the characteristics of the 
time course and extent of drug exposure in individuals and popu-
lations and deals with the absorption, distribution, metabolism, 
and excretion (ADME) of drugs. PK is defined as the mathemati-
cal description of temporal changes in concentration of drugs 
within the body (18); such studies provide the experimental basis 
for drug dosage regimens in various animal species.
Bioequivalence is a clinical term referring to formulations of 
a drug with rates and extents of absorption that are sufficiently 
similar that there are not likely to be any clinically important 
differences with respect to either efficacy or safety. In order to 
demonstrate bioequivalence for systemically active drugs, a 
comparative PK study is generally undertaken and the similarity 
(defined by statistical and biological criteria) of Cmax (maximum 
concentration) and AUC (area under curve) of the formulations 
is assessed. For drugs not acting systemically, comparisons of 
clinical or other pharmacological endpoints may be necessary.
In the development of dosage forms, there are many factors 
that must be standardized in order to ensure that the biologi-
cal availability of the active constituent is both predictable and 
reproducible. The following physicochemical and formulation-
induced factors have been described as sources of potential 
bioequivalence between products.
Toxicokinetics (TK) relies on the same principles as PK, but 
there are differences in data availability and aims. The exposure 
environment is characterized by the concentration of the toxi-
cant in the media, be it water, air, or feed, the quantities taken 
in, and the time course of the intake. Dose is the concentration, 
over time, of the toxicant in the various tissues of the subject 
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(cow, human, rat). The characterization of the kinetics linking 
exposure with dose is referred to as TK (for a toxic agent) or PK 
(for a pharmaceutical). In actual practice, the term pharmacoki-
netics is frequently used when it would be more appropriate to 
use the term toxicokinetics. Toxicokinetics are used to describe 
the movement and disposition of the toxicant in the organism. 
This includes consideration of the route of entry: ingestion, 
inhalation, dermal, or purposeful administration by injection. A 
complete description of the toxicokinetics of a toxicant will take 
into account (1) the intensity and duration of the exposure, (2) 
the rate and amount of absorption of the toxicant from the site 
of entry, (3) the distribution of the toxicant within the body, (4) 
potential biotransformation to less, equal, or more toxic form, 
and (5) the rate of excretion by route (urine, feces, or exhalation). 
All of these aspects of toxicokinetics may be influenced by spe-
cies differences in physiological and biochemical characteristics. 
Modern approaches to modeling toxicokinetics attempt to take 
account of both species differences and similarities in influencing 
the fate in the body of toxicants. It is also important to recognize 
that the exposure or dose level may influence the kinetics of a 
toxicant and its metabolite(s). This is an especially important 
consideration in extrapolating from laboratory studies that 
may be conducted at high doses to lower more environmentally 
relevant exposures/doses.
pharMacOKinetic/
pharMacOdynaMic predicted 
indeXeS
A PK/PD model is a mathematical description that provides 
clinically relevant information about the relationship between 
the pharmacokinetics and the pharmacological effect. There is a 
mounting body of evidence to support the use of PK/PD relation-
ship for individual antibacterial agents in identifying those doses 
and dose intervals that are most likely to be efficacious and least 
likely to result in adverse effects and/or the selection of resist-
ant organisms. This concept has implications for the safety and 
efficacy of antibacterial drugs (19). PK/PD modeling is a scien-
tific tool to help developers select a rational dosage regimen for 
confirmatory clinical testing. A PK/PD model integrates the PK 
model (describing the relationship between dose, systemic drug 
concentrations, and time) with the PD model (describing the 
relationship between systemic drug concentration and the effect 
vs. time profile) and a statistical model (particularly, the intra- 
and interindividual variability of PK and/or PD origin). PK/PD 
concepts can be applied to individual dose optimization (20). 
Aspects of PK/PD relationship through concept, basic theory, 
and practical data reinforced on data analysis and modeling 
and simulation, and a chance to play an active role in analysis, 
interpretation, and discussion will be welcome. Use of the PK/
PD relationship can be made to justify the dosages to be used 
in dose-determination studies. In some cases where the PK/PD 
relationship is well established using validated approaches, it may 
be possible to omit dose-determination studies and to confirm 
the efficacy of one or a very few dose regimens in clinical trials 
(dose confirmation and clinical field studies). To be acceptable, 
justification should be provided prospectively for the eligibility of 
such an approach (19). In conclusion, an effective antimicrobial 
should possess both PK and PD selectivity; it should distribute 
in the locus of the targeted pathogen, and it should have no PD 
impact on comensal microbiota of the gastrointestinal tract of 
the treated animal or on environmental ecosystems. Presently, 
we need to revise dosage regimens of the antimicrobial classes 
that are in the market and use preferentially narrow spectrum 
antimicrobials.
Veterinary drugs cover a broad range of chemical and class 
structures and usually undergo metabolism after any route of 
administration to an animal species. There are species differences 
in transformation and excretion on several drugs being the half-
live values different. Modes of administration include injection, 
implantation, dermal application by spray or pour-on, and inclu-
sion in feed or water, all of which may result in different rates 
of absorption, with possible differences in the tissue distribution 
and nature of the residues. Finally, as veterinary drugs are applied 
to a diverse group of target animals differing in species, breed, 
age, sex, and (patho)physiological status, the biological variance 
deserves to be given more attention not only in the developmental 
stage of new compounds but also at the stage of drug application 
by the practitioner (20).
Veterinary tOXicOlOGy
Veterinary toxicology is a very complex subject as it deals with 
a wide variety of poisons. The field of toxicology is very broad, 
including the identification and characterization of a number 
of toxicants (pharmaceuticals, food and feed additives, natural 
toxins, consumer products, and specific chemicals), their physical 
and chemical properties, their fate in the body, and their biologi-
cal effects. Currently, synthetic compounds constitute the largest 
number of chemicals that are frequently encountered in animal 
poisonings. Acute poisoning is a common presentation in emer-
gency veterinary medicine. Moreover, veterinary toxicology is 
concerned with the treatment of disease conditions caused by 
poisons. Currently, there is a need to integrate veterinary medi-
cine and specifically veterinary toxicology into environmental 
medicine.
The nature of the toxic responses depends not only on the toxi-
cant but also on the route of exposure, the duration, and intensity 
of the exposure, and the characteristics of the exposed individual 
(i.e., species, gender, age, preexisting disease states, nutritional 
status, and prior exposure to the agent or related compounds) 
(6). The subject of veterinary toxicology is complicated greatly 
by the wide variations in responses of domestic, aquatic, wild, 
and zoo species to toxicants. Of course, there are many other 
factors that can be involved in the overall toxicity of a chemi-
cal. Understanding the complete profile (especially mechanisms 
of toxicity) of each toxicant is the biggest challenge for today’s 
veterinary toxicologists (21).
Veterinary toxicology is a multifaceted hybrid that draws on 
and contributes to the veterinary medical profession, the scientific 
field of toxicology and, broadly, to medical science. Some have 
characterized toxicology as a distinct scientific discipline. I view 
toxicology as an applied area of science addressing important 
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societal issues by drawing on multiple scientific disciplines and 
professions (6). Veterinary toxicology had a much applied origin, 
involves the evaluation of toxicosis and deficiencies, identifica-
tion and characterization of toxins and determination of their 
fate in the body, and the diagnosis and treatment of toxicoses 
in domestic animals and companion animals. However, the field 
has broadened to include concern for contaminants in human 
food products originating from animals and for contributing 
to the conduct and interpretation of safety/risk evaluations for 
pharmaceuticals, food additives, consumer products, and specific 
chemicals.
The recent worldwide melamine contamination in pet and 
swine feed indicates the relevancy of veterinary toxicology to 
current animal health and food safety, particularly on its toxico-
logical aspects. Veterinary toxicology can be challenging because 
of the low frequency of cases observed in a practice setting. When 
a toxicosis occurs, it often involves a large number of animals and 
may also involve litigation (22).
Veterinary toxicologists who understand both normal and 
disease processes extending from the molecular level to the 
integrated mammalian organism and, indeed, populations, have 
an array of opportunities for making significant contributions to 
society (6).
In veterinary medicine, the discipline of clinical toxicology 
concerns the protection of companion, exotic/wildlife, and 
food-producing animals. Veterinary clinical toxicology links 
preventive and experimental toxicology with clinical veterinary 
medicine. Clinical animals are exposed to natural toxicants in 
their native environments, as well as to synthetic chemicals and 
drugs. The practicing veterinarian and the diagnostic or clinical 
veterinary toxicologist are often the first to respond to these 
problems, which may appear as a clinical syndrome of unknown 
cause. In veterinary medicine, understanding of sources of poi-
sons, circumstances of exposure, diagnosis of the type of poison-
ing, treatment, and application of management or educational 
strategies to prevent poisoning is of much interest. The clinical 
diagnosis may be used initially to determine the organ systems 
affected, and the disturbances that must be controlled to save the 
animal’s life and etiologic diagnosis is the most important diag-
nosis because it enables specific therapy and preventive measures 
to proceed. Clinical toxicology evaluation depends heavily on the 
determination of exposure and evidence for the contribution of 
interacting factors than can alter toxicity (23).
reGUlatOry pharMacOlOGy  
and tOXicOlOGy
Regulatory pharmacology and toxicology is the study of efficacy 
and adverse effects of chemicals not just on humans but also on 
all living organisms, including natural toxins, animals, fungi, and 
insects. Referring to regulatory toxicology supports the develop-
ment of standard protocols and new testing methods to continu-
ously improve the scientific basis for decision-making processes. 
It is the duty of the industrial pharmacologist and toxicologist 
to aid in the application, interpretation, and circumstantial 
evaluation of laws, rules, and regulations. Extensive regulatory 
and monitoring systems have been established to ensure that 
chemical residues in food do not constitute an unacceptable 
health risk. Chemicals (i.e., veterinary drugs, medicated feed, 
or application of pesticides) are everywhere, in the food we eat 
and in the feed of animals. Regulatory authorities establish MRLs 
or tolerances and set withdrawal periods that ensure residues of 
the pharmacologically active substance will not exceed the MRL 
when the label instructions for the product are followed (15). 
Some chemicals are used to help people and animals, such as the 
chemicals in medicines. Surveillance programs by comparison, 
sample target-tissues from animals suspected of violative residues 
on the basis of clinical signs or herd history. Animals identified 
with violative residues of veterinary drugs or pesticides do not 
enter the food chain. Most people know that high doses of some 
chemicals used to help them in medicines can damage health. The 
same can occur in the animals (22).
Veterinary toxicologists try to find out (1) what the toxic 
effects of chemicals are; (2) where toxic effects occur; (3) how a 
chemical causes its toxic effects, and (4) what length of exposure 
causes a toxic effect. Veterinary toxicologists often find out about 
the effects of chemicals by collecting data from laboratory experi-
ments on animals. They use their skills to predict what is likely 
to occur if humans come into contact with the same chemical. In 
laboratory studies, animals are often exposed to much higher lev-
els of a chemical than would normally be experienced by humans 
from normal use of that chemical. Toxicologists have developed a 
number of ways of predicting the likely effects at lower exposure 
levels.
The previous strong emphasis on field observations was first 
complemented and then supplemented by experimentation. 
This, in turn, led to the current strong mechanistic orientation 
of toxicology. With this shift in toxicology came an increased 
awareness of the utility of a comparative medicine orientation 
in research directed primarily toward improving human health 
(7). With this comparative medicine orientation came increased 
opportunities for individuals educated in veterinary medicine, 
including veterinary pharmacology and toxicology, to contribute 
to general pharmacology and toxicology and biomedical science.
Medicinal prOdUctS intended FOr 
MinOr USe Or MinOr SpecieS
There is considerable concern in the animal health sector about 
the lack of authorized veterinary medicinal products for minor 
uses and for minor species (MUMS). A “minor use” within EU 
member states may be a major use in other parts of the world 
where climate, diseases and disease vectors, environment, and 
husbandry practices differ from those in the EU. All other animal 
species that are not considered major [i.e., major food-producing 
species: cattle (dairy and meat animals), sheep (meat animals), 
pigs, chickens (including laying hens), and salmon; major 
companion animal species: cats, dogs]. All other animal species, 
which are not considered major, are as a consequence, by default, 
classed as minor species. Minor use in a major species is generally 
considered as the use of veterinary medicinal products for the 
treatment of diseases that occur infrequently or occur in limited 
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geographical areas and thus are indicated for a smaller market 
sector. The policy is intended to stimulate the development of 
new veterinary medicines for minor species and for diseases 
occurring infrequently or in limited geographical areas in major 
species that would otherwise not be developed in the current 
market conditions. For these reasons, the published guidelines 
are intended to reduce data requirements, where possible, for 
products classified as MUMS/limited market while still providing 
assurance of appropriate quality, safety, and efficacy and comply-
ing with the legislation in place and leading to an overall positive 
benefit–risk balance for the product (24). Studies on comparative 
metabolism may be of particular importance when assessing 
MRL recommendations for multiple species, particularly for the 
extension or extrapolation of MRLs to minor species. Where 
identical or very similar MRLs have been set for three major 
species from different animal classes (ruminants, monogastrics, 
and poultry), based on specific residue data, confirming a similar 
exposure situation of the consumer in relation to these species, it 
can be assumed that the exposure assessment and consequently 
the risk characterization on the basis of same/similar MRLs for 
further species beyond the animal classes concerned would be 
similar. The MRLs for chicken may be extended to turkeys based 
on similarity between the species (24).
tOXicity teStS
Toxicity test on laboratory animals are conducted to evaluate 
chemicals for their potential to cause cancer, birth defects, and 
other adverse health effects. Information from toxicity testing 
serves as the basis for regulatory decisions concerning toxic 
chemicals. Current test methods were developed incrementally 
over the past 50–60 years and are conducted using laboratory ani-
mals, particularly rats and mice. Test animals are often exposed 
to higher doses requiring assumptions about effects at lower 
doses or exposures. Often controversial uncertainty factors must 
be applied to account for differences between test animals and 
humans (25). The visional strategy for the replacement of animal 
testing by alternative approaches is based on the “3Rs principles” 
(Reduction, Replacement, and Refinement), which have been 
encouraged in particular in Europe. These principles have influ-
enced the modern state and perspectives of the development of 
non-animal experimental methods. While full replacement has 
not been achieved yet for those toxicological endpoints, partial 
replacement strategies to reduce the number of animals used 
exist. The term “alternative of animal testing” is generally associ-
ated with the “3Rs principles,” and was suggested due to animal 
welfare concerns (26).
In silico methods and in vitro systems are traditionally much 
used approaches to complement or partly replace animal tests in 
pharmacology and toxicology (26). The “integrated test strate-
gies,” which combine in silico, in vitro, and in vivo methods, allow 
the best predictions of toxicity.
Predominantly, predictive toxicological testing is derived 
from the findings to assess risks to animal, humans, and the 
environment. While traditional toxicology methods have relied 
heavily on animals, new high-throughput screening approaches 
to generate toxicological data are becoming increasingly available 
for the safety assessment of chemicals. Gene expression profil-
ing lends itself to two highly topical areas of drug development: 
“predictive” toxicology and mechanism-based risk assessment. 
The last few years have seen a lot of progress being made in link-
ing the profiles of gene expression induced by drugs with their 
toxicity (27).
Two recent reports prepared by Committees of the National 
Research Council provide insight into how some individuals 
envision the future of toxicity testing. The first NRC Report 
(28) addresses the application of toxicogenomic technologies 
in predictive toxicology and risk assessment. The second report 
provides a strategy and vision for toxicity testing in the twenty-
first century (25). Both committees would have benefited from 
participation by veterinarians who understand the complexity 
of disease processes and toxicoses to compensate for the view of 
molecular and cell biologists who focus on the microlevel and 
systems biology and may overstate the role of mathematical 
models (6). The term systems biology (biological integration) is 
a realization that organisms do not consist of isolated subsets of 
genes, proteins, and metabolites. It uses an integrated approach to 
study and understand the function of biological systems, and how 
perturbations of such systems (29). The key elements in systems 
biology are bioinformatics and mathematics that enable data 
integration and interpretation. Genomics and systems biology 
had a impact on various aspects of pharmacology, toxicology, 
and therapeutics; so approaches based on genomics and systems 
biology are now being used in various stages of drug discovery 
and development (30).
The concept of systems biology has come to the forefront 
in recent years. The concept of a systems approach to normal 
biology and disease processes has been a fundamental concept 
undergirding both veterinary medicine and human biology.
pharMacOGeneticS/
tOXicOGenOMicS
The linkage between dose and adverse health outcome involves 
multiple mechanisms as various toxicants may potentially impact 
all the cells and organ systems of the body. Increasingly, scientists 
have attempted to model these relationships, which, in parallel to 
the nomenclature for the kinetic phase, are called toxicodynamics 
(TD) or PD models. It is obvious that multiple pathways may be 
involved in a toxicant producing disease and that knowledge of 
the individual steps will increase as knowledge of basic biological 
mechanisms increases. For example, the explosion of knowledge 
of basic biology at the level of the genome (genomics), proteins 
(proteomics), and metabolism (metabolomics) has provided 
a basis for exploring the mechanistic basis of toxicant-induced 
disease with a degree of refinement that could not even be envi-
sioned even a short time ago. Genomics will also improve our 
understanding of comparative pharmacology and toxicology and 
thereby the rational use of animals and models (30).
The term genomics is used to encompass transcriptomics, 
proteomics, and metabolomics (or metabonomics) that describes 
the formation and fate of mRNA, proteins, and metabolites (30). 
The development of medium- to high-throughput methods in 
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proteomics, genomics, and metabolomics, together with the 
revolution in bioinformatics, will lead to the accumulation of vast 
toxicological information, helping to elucidate bioactivity and 
mechanisms of toxicity in both in vitro and in vivo models (31). 
These approaches will also help in the development and estab-
lishment of new biomarkers of effect or exposure. To be more 
efficient, considerable improvement in the use of novel technical 
tools (omics-based technology) for effective safety assessment 
is needed. Omics analysis are now being accepted as essential 
methodological parts of systems or integrative biology, and it is 
possible to observe global changes in all RNAs (transcriptom-
ics), proteins (proteomics), or metabolites (metabonomics, also 
called metabolomics, metabolic profiling, etc.) in cellular systems 
or tissues. This includes an array of new molecular biomarkers, 
which have received substantial attention. The omics will allow a 
comprehensive analysis of biological systems of many different 
animal species. Determination of the expression levels of multiple 
gene transcripts, proteins, and metabolites is now feasible and 
has been termed transcriptomics, proteomics, and metabolomics. 
Genomics can be used to identify new targets, since it is now 
possible to analyze changes in the transcription of >20,000 genes 
in various cell types and tissues in multiparameter experiments. 
There are two key approaches (1) the detection of cDNAs that 
correspond to the entire protein-encoding gene and (2) the use 
of RNAi to determine the relevance of mRNA levels in terms of 
protein expression and gene function. The transcriptomic data, 
and how they can be interpreted in the context of the pathology, 
and other biological data from a toxicology study are of much 
interest (30).
The toxicogenomics data have begun to be used more widely 
in the human health assessments of chemicals, and will likely 
be one of the crucial information sources for next-generation 
of risk assessment decisions. Given the general familiarity of the 
toxicologists with high-dimensional transcriptional profiling 
data and major traditional ways in which such data are analyzed, 
presented, and interpreted, this course is designed to demon-
strate how the toxicogenomics data can become a key element 
in hazard identification, dose-response analysis, and selection 
of scientifically justifiable uncertainty factors. By superimpos-
ing the opportunities that are now afforded by both traditional 
and high-throughput genomics data onto the human health 
assessment paradigm, this course will be informative to the risk 
assessment practitioners and the toxicology research community 
and increases the scientific impact of the fundamental toxicology 
studies.
High-throughput screening (HTS) allows identifying desirable 
PK properties or compounds with the greatest in vitro potency 
and/or efficacy and/or least toxicity. Development of improved 
hESCH-based HTS assays for cardiotoxicity assessment; cardiac 
toxicity is a major concern in drug development.
Toxicogenomics is a mature field, which provides invaluable 
information on the molecular events preceding or accompanying 
toxicity; however, most traditional use of gene expression and 
other ‘omic data in toxicology is largely the same as it was 10 years 
ago: the mode of action analysis, classification/prediction, and 
biomarker discovery. The toxicogenomics data have begun to be 
used more widely in the human health assessments of chemicals 
and will likely be one of the crucial information sources for next-
generation of risk assessment decisions. Given the general famili-
arity of the toxicologists with high-dimensional transcriptional 
profiling data and major traditional ways in which such data 
are analyzed, presented, and interpreted, this course is designed 
to demonstrate how the toxicogenomics data can become a 
key element in hazard identification, dose-response analysis, 
and selection of scientifically justifiable uncertainty factors. By 
superimposing the opportunities that are now afforded by both 
traditional and high-throughput genomics data onto the human 
health assessment paradigm, this course will be informative to the 
risk assessment practitioners and the toxicology research com-
munity and increases the scientific impact of the fundamental 
toxicology studies. Transcriptional and posttranslational signals 
are known mechanisms, which promote efficient responses to 
DNA damage (30). Using HTS assays and small molecule analysis 
approaches, can be identified translational components of the 
DNA damage response, which operate through the modification 
of tRNA. Multiple research efforts are looking to use high- and 
medium-throughput in vitro screening data in identifying chemi-
cal hazards. For industrial and agricultural chemicals, research 
efforts in United States and Europe have characterized the in vitro 
biological activity of chemicals using multiple in vitro assays and 
technologies in order to predict in  vivo toxicity and prioritize 
compounds for conventional toxicity testing. For pharmaceuti-
cals, high-throughput in vitro screening assays have been inte-
grated early into preclinical drug development to identify toxic 
compounds and guide medicinal chemistry efforts. In both cases, 
the application of in vitro toxicity screening for prioritization and 
hazard identification relies on its ability to accurately predict the 
results of in  vivo laboratory animal studies and humans. More 
recently, preclinical testing has been tailored to the specific prop-
erties and mode of action of the new drug and may be adapted on 
the outcome of previous studies (32).
The current objectives of toxicoproteomics in diagnostic 
toxicology is to define molecular mechanisms of toxicity, screen 
for drug toxicities, and elucidate biomarkers or signature protein 
profiles in order to more accurately assess, predict, and diagnose 
toxicities.
The use of proteomics for diagnostic application and the 
application of microscopic analyses of feeds and animal ingesta 
for toxic components in the diagnostic process are presented.
Veterinary MedicineS and 
enVirOnMental riSK
Advanced and developing societies are increasingly concerned 
with the impact of veterinary medicines on the environment 
(33). So, actually, an Environmental Risk Assessment (ERA) 
shall accompany an application for a marketing authorization 
for a medicinal product for veterinary use. The assessments 
are performed in two phases. In the first phase (Phase 1), the 
potential for environmental exposure is assessed according to 
the intended use of the veterinary medicine. The Phase 2 assess-
ment is performed in two parts, Tier A and Tier B. Assessment 
will stop at Tier A if the product has been shown to present no 
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risk. In Phase 1, the likelihood of exposure to the environment is 
assessed, and if the product does not meet certain criteria (e.g., if 
the soil PEC is greater then 100 μg/kg), then Phase 2 assessment 
is required. Phase 2 can be performed in two Tiers, in the first 
Tier, the likely impact of the substance is assessed using a range 
of standard tests, and the second Tier involves more detailed 
investigations into the compartment(s) of interest. A number 
of groups of veterinary medicines (i.e., fish farm medicines and 
anthelmintics) are known to be of environmental concern as 
well as the antimicrobials. After systemic administration, the 
substances can be metabolized and a mixture of the parent com-
pound and metabolites may be excreted in the urine and the feces, 
developing in the case of antimicrobials, their selective pressure 
on microbiota harbored by waste, manure/slurry, and beyond in 
water and soil. Some 70% of the antimicrobials administered to 
food-producing animals are excreted as active substances into 
the environment; furthermore, some antimicrobials are stable in 
the environment for weeks or months (34). Residues from farms 
may contain antibiotics and antibiotic resistance genes that can 
contaminate natural environments. The clearest consequence 
of antibiotic release in natural environments is the selection of 
resistant bacteria. The same resistance genes found at clinical 
settings are currently disseminated among pristine ecosystems 
without any record of antibiotic contamination. For animals 
on pasture, the excreta will be released directly to soil, whereas 
for intensively reared animals, the main route of entry will be 
through slurry and manure spreading. Although there has long 
been concern over the use of chemical additives in livestock 
feed (e.g., potential consequences of insect-free manure), the 
effects on non-target dung insects and dung dispersal primarily 
become a concern with some drugs (e.g., macrocyclic lactones). 
For example, the introduction of doramectin into environment 
will be intermittent through the field application of sheep manure 
containing excreted drug residues or by direct defecation by sheep 
of manure containing doramectin residues. In order to assess the 
risks posed to the environment by veterinary medicines used to 
treat livestock, a number of models based on assumptions derived 
from experience with pesticides, industrial chemicals, and 
guidelines have been developed for regulatory agencies predict-
ing concentrations of veterinary medicines in soil, groundwater, 
and surface waters. The potential impact of a veterinary medicine 
on the environment will be determined by a number of factors, 
including amount used, usage pattern, metabolism, persistence 
in manure and slurry, sorption and persistence in the environ-
ment, and ecotoxicity. Veterinary medicines can persist in soils 
for days to years, and studies have demonstrated that half-lives 
are influenced by a range of factors, including temperature, pH, 
and the presence of manure.
antiMicrOBialS and anthelMinticS 
reSiStance
Antimicrobial resistance (AMR) is the resistance of a micro-
organism to an antimicrobial drug to which it was previously 
sensitive. Resistant organisms (they include bacteria, viruses, 
and some parasites) are able to withstand attack by antimicrobial 
medicines, such as antibiotics, antivirals, and antimalarials, so 
that standard treatments become ineffective, and infections 
persist and may spread to others. Antibiotics have revolutionized 
the treatment of infectious diseases, but there are public health 
concerns that efficacy of antimicrobials in man is compromised 
by their use in animals. Antimicrobial resistence is a consequence 
of the use, particularly the misuse, of antimicrobial medicines and 
develops when a microorganism mutates or acquires a resistance 
gene. This issue is now a significant health problem, each year 
in the European Union (EU) alone, over 25,000 people die from 
infections caused by antibiotic-resistant bacteria. Infections due 
to these selected multidrug-resistant bacteria in the EU result 
in extra health-care costs and productivity losses of at least €1.5 
billion each year. If the current trend is not altered, 300 million 
people worldwide are expected to die prematurely because of 
drug resistance over the next 35 years (35).
Antimicrobial resistance spreads through global tourism, 
transfer of patients between health-care facilities within and from 
outside the EU, and through trade in food and animals. It is an 
important global economic and a societal challenge that cannot be 
tackled by countries or public administrations alone. Therefore, 
the problem needs a comprehensive “One Health” approach to 
it. That means that a holistic, multi-sectorial approach involv-
ing many different sectors (public health, food safety, biosafety, 
environment, research and innovation, international coopera-
tion, animal health and welfare as well as non-therapeutic use of 
antimicrobial substances) is needed to take care of this complex 
problem.
Antibiotic resistance is also a food safety problem: antibiotic 
use in feed – for treatment, disease prevention, or growth promo-
tion – allows resistant bacteria and resistance genes to spread from 
food animals to humans through the food chain. The horizontal 
transfer of resistant bacteria from living animal to humans has 
been documented for methicillin-resistant Staphylococcus aureus 
(MRSA) investigated in pigs, cattle, horses, and domestic pets. 
Although most S. aureus infections are hospital acquired, trans-
mission of MRSA from pigs to pig farmers and their families has 
been documented (36), but these transmissions concerning the 
livestock MRSA (ST398) seem to be low in humans. Livestock-
acquired MRSA in contrast to the hospital-acquired MRSA 
(HA-MRSA) strains has a very low pathogenicity, and it is hardly 
transmitted horizontally between humans. The same can be indi-
cated for Escherichia coli isolates expressing extended spectrum 
β-lactamases (ESBLs). The issue of MRSA in food animals is an 
emerging concern.
Recently, it has been discovered that there is a new mechanism 
of resistance in bacteria to colistin (caused by the mcr-1 gene). 
The gene can be transferred between different types of bacteria, 
potentially causing a rapid development of resistance. The gene 
was first identified in bacteria (Enterobacteriaceae) in South 
China (37), and since then has also been found in the EU and 
other regions. In addition, colistin should be reclassified and 
added to Category 2 of the AMEG (Antimicrobial Advice ad 
hoc Expert Group of European Medicines Agency) classification 
system, which includes medicines reserved for treating infections 
in animals for which no effective alternative treatments exist. This 
category includes certain classes of antimicrobials listed by the 
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World Health Organization as critically important in human 
health, especially fluoroquinolones and third- and fourth-
generation cephalosporins, only be used in food animals when 
their use is justified and under specific restrictions. Responsible 
(prudent) use of antibiotics is an essential element in the fight 
against antibiotic resistance.
It is probable that one of the most effective measures to limit 
expansion of AMR is reducing the need for antibiotics in animal 
husbandry by improving animal health through biosecurity 
measures, disease prevention (including the introduction of 
effective vaccines, modulation of the innate immunocompetence, 
bacteriophage therapy), and good hygienic and management 
practices; and eliminating economic incentives that facilitate the 
inappropriate prescription of antibiotics. More targeted use of 
antimicrobials were still necessary to guard animal health (e.g., by 
the use of accurate diagnosis, evidence-based regional treatment 
guidelines, and correct dosing regimens). It is noticeable that it is 
necessary to provide improved summary product characteristics 
(SPC) guidance about the epidemiological circumstances under 
which this has shown to be effective and the extent of benefit 
demonstrated. Veterinary pharmacology contributes to make 
rational dosage schedule design and to minimize its emergence 
and spread.
There is now a need to develop veterinary medicines, which 
reduce the need for use of antimicrobials (“alternatives”), such as 
vaccines, and will facilitate the regulatory pathway for innovative 
products and novel therapies. Furthermore, there is now a need 
to develop new compounds having minimal impact on gut flora 
and on environmental bacterial ecosystems (34).
The development of nematode and trematode resistance to 
various groups of anthelmintics is a major problem. Compared 
with the development of AMR, resistance to anthelmintics in 
nematodes has been slow to develop under field conditions.
aniMal Feed cOntaMinatiOn
In the last years, the animal feed productions have had several 
contamination crises, such as transmissible bovine encephalitis 
caused by prions, unexpected sources of dioxin contamination of 
milk, meat, and eggs (38), and the presence of residues or unau-
thorized substances, such as melamine in milk, milk products, and 
animal feeds (39). Feed hygiene is another important subject to 
be highlighted because of contamination with enterobacteriaceae 
and anaerobes and the presence on environmental pollutants 
and contaminants, such as persistent organic pollutants (POPs), 
present in a broad variety of feed material and able to accumulate 
in animal tissues (i.e., dioxins and dioxin-like polychlorinated 
biphenyls and brominated flame retardants). Toxic heavy metals 
and other chemical elements and natural toxins, such as toxic 
plant metabolites and bacterial and fungal toxins, can be present 
in feed for animal consumption.
In recent years, increasing attention has been paid to the risk to 
consumers posed by chemical contaminants or residues in animal 
feed. This was caused by various cases of milk, eggs, or other ani-
mal products contaminated with environmental chemicals. For 
that, large number of emerging chemical contaminants in feed 
require the establishment of maximum limits (MLs).
The carry-over or cross-contamination from feed to food 
must be determined from animal experiments throughout the 
so-called transfer factors of chemicals from animal feed to animal 
products. The transfer factor is expressed as the concentration of 
the chemical in the animal food products (milligram/kilogram 
wet weight) divided by the concentration of the chemical in the 
animal feed (milligram/kilogram dry weight). Leeman et al. (40) 
have compiled data on transfer rates from a number of chemi-
cal contaminants in food products [i.e., pesticides, dioxins and 
furans, polychlorobiphenyls (PCBs), and polybrominated biphe-
nyls (PBBs), heavy metals, mycotoxins, hormones, veterinary 
medicines, nitrosamines, and other compounds not belonging to 
one of the previous classes]. If a study on the carry-over is not 
available, a conservative worst-case estimate considers that all of 
the contaminant consumed is transferred to the animal product, 
e.g., the meat.
Carry-over or cross-contamination has been evaluated with 
some coccidiostats, particularly polyether ionophore. The health 
risk to non-target species resulting from the consumption of 
cross-contaminated feed with coccidiostats at levels of 2, 5, 
or 10% was evaluated recently by the European Food Safety 
Authority (EFSA) and a revision of the risk assessments is found 
in the paper of Dorne et al. (41).
To tackle these current and future challenges, we need to 
advance scientific knowledge through the application of novel 
approaches. Likewise, for an effective translation of scientific 
discoveries and applications in the field of veterinary pharma-
cology and toxicology, we need an outlet to enhance effective 
communication among scientists with different backgrounds 
and who share a common interest in veterinary pharmacology 
and toxicology. This was the drive for launching a veterinary 
pharmacology and toxicology specialty section in the journal 
Frontiers in Veterinary Science, an international, open-access, 
peer-reviewed, online journal. It gives me great pleasure to 
announce the inauguration of this new veterinary pharmacol-
ogy and toxicology specialty section with the ethos of publish-
ing the most impactful and interesting research discoveries in 
basic and fundamental areas of pharmacology and toxicology. 
The veterinary pharmacology and toxicology specialty section 
will publish original research articles and reviews of latest 
developments in specific subject areas and forward-looking 
perspectives.
As the founding Specialty Chief Editor for veterinary 
pharmacology and toxicology Frontiers in Veterinary Science, I 
have accepted the challenges and responsibilities of developing 
a premier professional journal in veterinary pharmacology and 
toxicology. The editorial team will strive to maintain excellence 
while improving the efficiency of the review process and taking 
advantage of the latest online technology. All editorial board 
members are leaders in their respective scientific areas and are 
willing to devote their time and expertise to build a journal of 
excellence to serve the veterinary pharmacology and toxicol-
ogy research community, and life sciences in general, with the 
ultimate goal of improving animal and human lives. I do hope 
that the veterinary pharmacology and toxicology section will 
appeal to readers with veterinary, medical, and life science 
interests.
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Veterinary pharMacOlOGy and 
tOXicOlOGy iS a Specialty SectiOn 
OF FrOntierS in Veterinary Science
Veterinary Pharmacology and Toxicology provides an interna-
tional publication forum for scientists and clinicians investigating 
drugs and toxins in all animal species (livestock, poultry, game 
birds, avian, rabbits, companion animals, horses, wildlife, zoo 
animals, farmed fish and shellfish, bees, and laboratory animals). 
The section welcomes high quality original manuscripts in all 
topics of pharmacology and toxicology, including pharmacody-
namics/toxicodynamics; pharmacogenetics/pharmacogenomics; 
toxicogenetics/toxicogenomics; pharmacokinetics/toxicokinet-
ics; adverse effects of drugs, xenobiotics, plants and toxins; 
contaminants, pesticides, and drug residues in food animals and 
food products; clinical pharmacology and therapeutics; clinical 
toxicology; environmental toxicology; AMR; and regulatory 
pharmacology and toxicology. Veterinary pharmacology and 
toxicology welcomes submissions in traditional as well as new 
and emerging areas of research, encourages interdisciplinary 
studies, and seeks to advance global progress in these important 
disciplines.
I look forward to receiving your exciting research contribu-
tions in these areas. Your ideas and suggestions for making 
the journal highly impactful are welcomed and will be always 
valued.
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